Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00052455 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : December 18, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating recurrent malignant glioma.
PURPOSE: Randomized phase III trial to compare the effectiveness of temozolomide alone to that of procarbazine, lomustine, and vincristine in treating patients who have recurrent malignant glioma.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain and Central Nervous System Tumors | Drug: lomustine Drug: procarbazine hydrochloride Drug: temozolomide Drug: vincristine sulfate | Phase 3 |
OBJECTIVES:
- Compare the efficacy of temozolomide vs procarbazine, lomustine, and vincristine, in terms of overall survival, in patients with recurrent malignant glioma.
- Compare progression-free survival of patients treated with these regimens.
- Compare progression-free survival at 12 weeks in patients treated with two different schedules of temozolomide.
- Compare the overall survival of patients treated with two different schedules of temozolomide.
- Compare toxic effects of two different schedules of temozolomide in these patients.
- Compare quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.
-
Arm I:Patients are randomized to 1 of 2 treatment schedules:
- Schedule 1: Patients receive oral temozolomide once daily on days 1-5.
- Schedule 2:Patients receive oral temozolomide once daily on days 1-21. Treatment on both schedules repeats every 4 weeks for a maximum of 9 courses in the absence of disease progression or unacceptable toxicity.
- Arm II:Patients receive oral lomustine and vincristine IV on day 1 and oral procarbazine on days 1-21. Treatment repeats every 6 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at 12 and 24 weeks.
Patients are followed every 12 weeks.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 500 patients (250 per treatment arm) will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 500 participants |
Allocation: | Randomized |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV |
Study Start Date : | October 2002 |
Actual Study Completion Date : | September 2010 |

- Overall survival
- Progression-free survival at 12 weeks (Arm II)
- Toxicity
- Overall survival
- Quality of life as measured by EORTC QLQ-C30 and BTM
- Cost effectiveness

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed anaplastic astrocytoma, glioblastoma multiforme, or gliosarcoma
- WHO grade III or IV at diagnosis or relapse
- Must have undergone primary therapy including radiotherapy
- Must be in first recurrence confirmed by CT scan or MRI
- Evaluable disease by CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- WHO 0-3
Life expectancy
- At least 1 month
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Total and direct bilirubin less than 1.5 times upper limit of normal (ULN)
- SGOT or SGPT less than 3 times ULN
- Alkaline phosphatase less than 2 times ULN
Renal
- BUN less than 1.5 times ULN
- Creatinine less than 1.5 times ULN
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other concurrent serious illness
- Considered fit to receive chemotherapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for glioma
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- At least 2 months since prior radiotherapy
- No prior radiosurgery, interstitial radiotherapy, or brachytherapy for glioma
Surgery
- Prior debulking surgery for recurrent disease allowed

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00052455
United Kingdom | |
Medical Research Council Clinical Trials Unit | |
London, England, United Kingdom, NW1 2DA |
Study Chair: | Simon Clawson | Medical Research Council |
ClinicalTrials.gov Identifier: | NCT00052455 |
Other Study ID Numbers: |
CDR0000258428 MRC-BR12 EU-20114 ISRCTN83176944 |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | December 18, 2013 |
Last Verified: | May 2007 |
adult glioblastoma adult anaplastic astrocytoma recurrent adult brain tumor adult giant cell glioblastoma adult gliosarcoma |
Nervous System Neoplasms Central Nervous System Neoplasms Neoplasms by Site Neoplasms Nervous System Diseases Vincristine Temozolomide Lomustine Procarbazine |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Alkylating Alkylating Agents |